Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH-Reference-Cited by-同舟云学术

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

Published:2017-11-09 Issue:12 Volume:15 Page:2461-2465
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Iorio A.¹²^ORCID,Blanchette V.³,Blatny J.⁴,Collins P.⁵,Fischer K.⁶,Neufeld E.⁷,

Affiliation:

1. Department of Health Research, Methods, Evidence and Impact; McMaster University; Hamilton Ontario Canada

2. Department of Medicine; McMaster University; Hamilton Ontario Canada

3. Division of Hematology/Oncology; Hospital for Sick Children and Department of Pediatrics; University of Toronto; Toronto Ontario Canada

4. Department of Pediatric Hematology; University Hospital Brno; Brno Czech Republic

5. Arthur Bloom Haemophilia Centre; School of Medicine; University Hospital of Wales; Cardiff University; Cardiff UK

6. Van Creveldkliniek; University Medical Center; Utrecht the Netherlands

7. St Jude Children's Research Hospital; Memphis TN USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13867/fullpdf

Reference30 articles.

1. Lee M Morfini M Schulman S Ingerslev J the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors http://www.isth.org/Publications/OfficialCommunications/Factor8and9/Pharmacokinetic.asp

2. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis;Morfini;Thromb Haemost,1991

3. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia;Collins;Haemophilia,2011

4. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years;Björkman;Eur J Clin Pharmacol,2009

5. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A;McEneny-King;Expert Opin Drug Metab Toxicol,2016

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis;Journal of Thrombosis and Haemostasis;2023-12

2. Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, A full-length recombinant factor VIII, in pediatric patients with haemophilia A;Thrombosis Research;2023-12

3. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

4. Expanding Pharmacy Services to the Hemophilia Treatment Center;Hospital Pharmacy;2023-04-13

5. Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation;Blood Coagulation & Fibrinolysis;2023-04